Clinical Trial

Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease

Study acronym: cTDCSinPD
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Background \& Rationale: Treatment options for Parkinson's Disease (PD) often face challenges due to the variety of clinical subtypes, differing individual responses, and disease progression. Given its portability, affordability, safety, and ease of use, cerebellar transcranial direct current stimulation (ctDCS) presents as a promising option for home-based treatment with medical telemonitoring in the near future. Study Procedures: Participants are invited to complete questionnaires regarding quality of life, anxiety and depression, and symptoms related to their PD. On the first day, they will be assessed using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III for motor impairment and the Cerebellar Cognitive Affective Syndrome scale (CCAS) for cognitive impairment. Participants will then undergo an additional 8 days of at-home cTDCS stimulation. On the 10th day, they will be reassessed using the MDS-UPDRS III and CCAS. One month later, they will complete again the questionnaires regarding quality of life, anxiety, depression, and symptoms related to their PD. Objective: Consequently, the primary goal is to investigate the effectiveness of ctDCS in addressing both motor and non-motor symptoms of PD
Trial Details
NCT Number NCT07548801
Lead Sponsor Université Libre de Bruxelles
Collaborators: Fonds National de la Recherche Scientifique
Conditions PARKINSON DISEASE (Disorder)
Enrollment 25 participants
Start Date 2025-09-24
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-23